BioCentury | Apr 15, 2013
Company News

Select Therap scientific advisory board update

Select Therapeutics Inc. (SLPU), Ottawa, Ontario Business: Diagnostics/Imaging Appointed: Allan Green, VP of pharmaceutical/biomedical products for ML Strategies Inc., as chairman WIR Staff Diagnostic...
BioCentury | Feb 3, 2003
Company News

AlphaRx, Select Therap deal

...Nov. 18, 2002). The compound is in preclinical development. AlphaRx Inc. (ALRX), Richmond Hill, Ontario Select Therapeutics Inc....
BioCentury | Nov 18, 2002
Company News

AlphaRx, Select Therap deal

...and kill tumors bearing a receptor specific for VeroPulse. AlphaRx Inc. (AHRX), Richmond Hill, Ontario Select Therapeutics Inc....
BioCentury | Apr 29, 2002
Company News

Select Therap board of directors update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Appointed: Andrew Muir, as chairman; he replaces Robert Bender, who departed WIR Staff...
BioCentury | Apr 29, 2002
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Transition: Craig Sibley, a co-founder, to president, CEO and a director; he replaces Andrew Muir WIR Staff cancer...
BioCentury | Apr 8, 2002
Company News

Generex management update

...delivery, Metabolic Hired: Steven Peltzman as VP of business development and licensing, formerly CEO of Select Therapeutics Inc. WIR...
BioCentury | Nov 5, 2001
Company News

Cytomatrix LLC, Select Therap deal

...to Cytomatrix. Additionally, XZL said it is seeking strategic alternatives. Cytomatrix LLC , Woburn, Mass. Select Therapeutics Inc....
BioCentury | Nov 5, 2001
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Gene/Cell therapy Transition: Douglas McNair to SVP of R&D from SVP of clinical and regulatory affairs WIR Staff...
BioCentury | Oct 8, 2001
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Hired: Douglas McNair as SVP of Clinical and Regulatory Affairs, formerly VP of clinical affairs at Abiomed Inc. WIR Staff cancer...
BioCentury | Oct 8, 2001
Company News

Neurochem, Select Therap deal

...Verovax technology to deliver NRM's AD antigens to dendritic cells. Neurochem Inc. (TSE:NRM), Saint-Laurent, Quebec Select Therapeutics Inc....
Items per page:
1 - 10 of 43
BioCentury | Apr 15, 2013
Company News

Select Therap scientific advisory board update

Select Therapeutics Inc. (SLPU), Ottawa, Ontario Business: Diagnostics/Imaging Appointed: Allan Green, VP of pharmaceutical/biomedical products for ML Strategies Inc., as chairman WIR Staff Diagnostic...
BioCentury | Feb 3, 2003
Company News

AlphaRx, Select Therap deal

...Nov. 18, 2002). The compound is in preclinical development. AlphaRx Inc. (ALRX), Richmond Hill, Ontario Select Therapeutics Inc....
BioCentury | Nov 18, 2002
Company News

AlphaRx, Select Therap deal

...and kill tumors bearing a receptor specific for VeroPulse. AlphaRx Inc. (AHRX), Richmond Hill, Ontario Select Therapeutics Inc....
BioCentury | Apr 29, 2002
Company News

Select Therap board of directors update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Appointed: Andrew Muir, as chairman; he replaces Robert Bender, who departed WIR Staff...
BioCentury | Apr 29, 2002
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Transition: Craig Sibley, a co-founder, to president, CEO and a director; he replaces Andrew Muir WIR Staff cancer...
BioCentury | Apr 8, 2002
Company News

Generex management update

...delivery, Metabolic Hired: Steven Peltzman as VP of business development and licensing, formerly CEO of Select Therapeutics Inc. WIR...
BioCentury | Nov 5, 2001
Company News

Cytomatrix LLC, Select Therap deal

...to Cytomatrix. Additionally, XZL said it is seeking strategic alternatives. Cytomatrix LLC , Woburn, Mass. Select Therapeutics Inc....
BioCentury | Nov 5, 2001
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Gene/Cell therapy Transition: Douglas McNair to SVP of R&D from SVP of clinical and regulatory affairs WIR Staff...
BioCentury | Oct 8, 2001
Company News

Select Therap management update

Select Therapeutics Inc. (XZL), Woburn, Mass. Business: Cancer Hired: Douglas McNair as SVP of Clinical and Regulatory Affairs, formerly VP of clinical affairs at Abiomed Inc. WIR Staff cancer...
BioCentury | Oct 8, 2001
Company News

Neurochem, Select Therap deal

...Verovax technology to deliver NRM's AD antigens to dendritic cells. Neurochem Inc. (TSE:NRM), Saint-Laurent, Quebec Select Therapeutics Inc....
Items per page:
1 - 10 of 43